TACSTD2 and colorectal carcinoma: Additionally, genetic testing revealed that CRC patients with KRAS, NRAS, and BRAF mutations had higher Trop2 expression levels compared to WT patients, with similar trends observed in both Trop2-positive area and expression intensity.